Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sernova Corp T.SVA

Alternate Symbol(s):  SEOVF

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases requiring replacement of these molecules in the body.


TSX:SVA - Post by User

Post by BioTeckon Jun 07, 2022 6:13pm
229 Views
Post# 34738570

Dose of reality

Dose of realityFor those who are looking at things positively. May 2018, we got green light to start clinical trial. So 4 long years later we have 3 people out of 7 with cell pouches. That is less than 1 person per year. The study is slated for preliminary completion in July 2022. So obviously that won't be happening. If past performance is any indication of future performance we still have 3 more years to go before they complete the study. Patient 7 seems to be harder to find than Waldo. Is it a surprise given our management? They managed to do 2 years of secret collaboration with Sanofi/Evotec. They have secret collaborations with 2 other Pharma's which everyone probably already knows about. If spill wasn't such a tool and released news when it happens instead of signing nonhdisclosures and sitting on it and letting it slowly leak through his various IR, we'd be in much better shape. He has zero business acumen and belongs in the lab and the lab only. This year we are on the TSX, so I am looking forward to the voting results. See how close we are to get rid of the dead weight that plagues this stock. So those wondering why the stock isn't moving it's because there is years of time remaining before anything happens that COULD lift the stock. Remember it could also TANK it if the bigger pouch doesn't do as promised. https://clinicaltrials.gov/ct2/show/NCT03513939
<< Previous
Bullboard Posts
Next >>